PUBLICATIONS: VOCKERODT

ORIGINAL PAPERS

1. Mohamed G, Vrzalikova K, Cader FZ, Vockerodt M, Nagy E, Flodr P, Yap LF, Diepstra A, Kluin PM, Rosati S and Murray P (2014). Epstein-Barr virus, the germinal centre and the development of Hodgkin's lymphoma. J Gen Virol., 95, 1861-1869.

2. Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler MA, Kearns P, Murray PG (2013). The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood,122, 4237-45

3. Smith N, Tierney R, Wei W, Vockerodt M, Murray PG, Woodman CB, Rowe M (2013) Induction of interferon-stimulated genes on the IL-4 response axis by Epstein-Barr virus infected human B cells; relevance to cellular transformation. PLoS One, 27, 64868.

4. Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG (2013). Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle. J Pathol., 230, 399-409.

5. Walther N, Ulrich A, Vockerodt M, von Bonin F, Klapper W, Meyer K, Eberth S, Pukrop T, Spang R, Trümper L, Kube D (2013). Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma. Am J Pathol., 182, 1092-8

6. Schrader A, Meyer K, von Bonin F, Vockerodt M, Walther N, Hand E, Ulrich A, Matulewicz K, Lenze D, Hummel M, Kieser A, Engelke M, Trümper L, Kube D (2012). Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas. Cell Commun Signal., 10: 43

7. Schrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, Arrand JR, Murray PG, Trümper L, Kube D, Vockerodt M (2012). High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer, 131, 348-61

8. Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray PG, Woodman CB (2011). Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin's lymphoma. J Virol., 85, 9568-77.

9. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG (2011). Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood, 117, 5907-17

10. Anderton JA, Bose S, Vockerodt M, Vrzalikova K, Wei W, Kuo M, Helin K, Christensen J, Rowe M, Murray PG, Woodman CB (2011). The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma. Oncogene, 30, 2037-43

11. Schain F, Tryselius Y, Sjöberg J, Porwit A, Backman L, Malec M, Xu D, Vockerodt M, Baumforth KR, Wei W, Murray PG, Björkholm M, Claesson HE (2008). Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma. Int J Cancer, 123, 2285-93

12. Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, Young LS, Woodman CB, Murray PG (2008). The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol., 216, 83-92

13. Dutton A, Woodman CB, Chukwuma MB, Last JI, Wei W, Vockerodt M, Baumforth KR, Flavell JR, Rowe M, Taylor AM, Young LS, Murray PG (2007). Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood, 109: 2597-603

14. Vockerodt M, Pinkert D, Smola-Hess S, Michels A, Ransohoff R, Tesch H, and Kube D (2005). The Epstein Barr Virus oncoprotein Latent Membrane Protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation. Int J Cancer, 114, 598-605

15. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Loffler D, Horn F, Trumper L, Kube D (2005). STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia, 19, 936-44

16. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Stevanovic S, Tuschl T and Münz C (2005). Endogenous MHC class II processing of a viral nuclear antigen 1 by lysosomes after autophagy. Science, 307, 593-596

17. Thomas RK, Wickenhauser C, Kube D, Tesch H, Diehl V, Wolf J, and Vockerodt M (2004). Repeated clonal relapses in classical Hodgkin's lymphoma and the occurrence of a clonally unrelated diffuse large B cell non-Hodgkin lymphoma in the same patient. Leukemia and Lymphoma, 45, 1065-1069.

18. Kube D, Mörmann M, Tomiuk J, Hua T, Kremsner P and Vockerodt M (2003). Simultaneous analysis of interleukin-10 gene microsatellites and single-nucleotide polymorphisms in parallel with tumour necrosis factor and interferon-gamma short tandem repeats by fluorescence-based polymerase chain reaction. Genes and Immunity, 4, 459-468.

19. Vockerodt M, Belge G, Kube D, Irsch J, Siebert R, Tesch H, Diehl V, Wolf J, Bullerdiek J and Staratschek-Jox A (2002). An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591. Br J Haematol., 119, 640-646.

20. Thomas R, Kallenborn A, Wickenhauser C, Schultze J, Draube A, Vockerodt M, Re D, Diehl V and Wolf J (2002). Constitutive Expression of c-FLIP in Hodgkin and Reed-Sternberg Cells. Amer J Pathol., 160, 1521-1528.

21. Vockerodt M, Tesch H and Kube D (2001). Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NF kappaB pathway. Genes and Immunity, 2, 433-441.

22. Vockerodt M, Haier B, Buttgereit P, Tesch H and Kube, D (2001). The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology, 280, 183-198.

23. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V and Tesch H (2001). STAT3 is constitutively activated in Hodgkin cell lines. Blood, 98, 762-770.

24. Draube A, Pfister R, Vockerodt M, Schuster S, Kube D, Diehl V and Tesch H (2001). Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Annals of Hematology, 80, 83-89.

25. Kube D, Vockerodt M, Weber O, Hell K, Wolf J, Haier B, Graesser FA, Mueller Lantzsch N, Kieff E, Diehl V and Tesch H (1999). Expression of Epstein-Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. Journal of Virology, 73, 1630-1636.

26. Kornacker M, Jox A, Vockerodt M, Tesch H, Bohlen H, Diehl V and Wolf J (1999). Detection of d Hodgkin/Reed-sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin´s disease. Br J Haematol. 106, 528-531.

27. Jox A, Taquia E, Vockerodt M, Draube A, Pawlita M, Moller P, Bullerdiek J, Diehl V, Wolf J (1999). Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss. Cancer Res., 58, 4930-4939.

28. Vockerodt M, Soares M, Kanzler H, Küppers R, Kube D, Hansmann ML, Diehl, V., and Tesch, H. (1998). Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged V(H) genes in different biopsies in relapsed Hodgkin's disease. Blood, 92, 2899-2907.

Reviews

1. Cader FZ, Kearns P, Young L, Murray P, Vockerodt M (2010). The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev., 36, 348-53

2. Kube D and Vockerodt M (2001). Transient gene expression and MACS enrichment. Methods Mol. Biol. 174, 155-164.